OKYO Pharma logo

OKYO - OKYO Pharma News Story

11.25p -0.3  -2.2%

Last Trade - 4:28pm

Sector
Healthcare
Size
Small Cap
Market Cap £73.2m
Enterprise Value £73.0m
Revenue £n/a
Position in Universe 1053rd / 1803

OKYO Pharma Limited - Notice of Results: AGM

Fri 25th September, 2020 12:00pm
RNS Number : 1402A
OKYO Pharma Limited
25 September 2020
 

FOR IMMEDIATE RELEASE

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

 

25 September 2020

OKYO Pharma Limited

("OKYO" or the "Company")

 

RESULT OF THE ANNUAL GENERAL MEETING

 

OKYO, the life sciences and biotechnology company, focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain, is pleased to announce that at the annual general meeting (the "Annual General Meeting") held earlier today the proposed resolutions set out in the notice of Annual General Meeting dated 9 September 2020 were duly passed.

The results of the proxy voting will be available shortly on the Company's website, https://www.okyopharma.com/news/.

The person who arranged for the release of this announcement on behalf of the Company was Keeren Shah, Chief Financial Officer of OKYO.

About OKYO

OKYO Pharma Limited (LSE: OKYO) is a life sciences and biotechnology company admitted to listing on the standard segment of the Official List of the UK Financial Conduct Authority and to trading on the Main Market for listed securities of the London Stock Exchange plc. OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain.

Enquiries:

OKYO Pharma Limited

Willy Simon

+44 (0)20 7382 8300

Optiva Securities Limited

 

Robert Emmet

+44 (0)20 3981 4173

For further information, please visit the Company's website at www.okyopharma.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGUVAWRRKUKURR
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.